Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics
Authors:
Open Access
- 23 February 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 211 (suppl 1) , S1-S20
Abstract
Two meetings, one sponsored by the Wellcome Trust in 2012 and the other by the Global Virology Foundation in 2013, assembled academic, public health and pharmaceutical industry experts to assess the challenges and opportunities for developing antivirals for the treatment of respiratory syncytial virus (RSV) infections. The practicalities of clinical trials and establishing reliable outcome measures in different target groups were discussed in the context of the regulatory pathways that could accelerate the translation of promising compounds into licensed agents. RSV drug development is hampered by the perceptions of a relatively small and fragmented market that may discourage major pharmaceutical company investment. Conversely, the public health need is far too large for RSV to be designated an orphan or neglected disease. Recent advances in understanding RSV epidemiology, improved point-of-care diagnostics, and identification of candidate antiviral drugs argue that the major obstacles to drug development can and will be overcome. Further progress will depend on studies of disease pathogenesis and knowledge provided from controlled clinical trials of these new therapeutic agents. The use of combinations of inhibitors that have different mechanisms of action may be necessary to increase antiviral potency and reduce the risk of resistance emergence.Keywords
This publication has 173 references indexed in Scilit:
- Activation of protein kinase R is required for induction of stress granules by respiratory syncytial virus but dispensable for viral replicationVirology, 2011
- A Lean LaboratoryThe Journal of Molecular Diagnostics, 2011
- The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic childrenJournal of Allergy and Clinical Immunology, 2010
- Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysisThe Lancet, 2010
- A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virusProceedings of the National Academy of Sciences, 2010
- Generation of stable monoclonal antibody–producing B cell receptor–positive human memory B cells by genetic programmingNature Medicine, 2009
- Surface features of a Mononegavirales matrix protein indicate sites of membrane interactionProceedings of the National Academy of Sciences, 2009
- The Burden of Respiratory Syncytial Virus Infection in Young ChildrenNew England Journal of Medicine, 2009
- Respiratory syncytial virus uses a Vps4-independent budding mechanism controlled by Rab11-FIP2Proceedings of the National Academy of Sciences, 2008
- Respiratory Syncytial Virus Infection and Disease in Infants and Young Children Observed from Birth in Kilifi District, KenyaClinical Infectious Diseases, 2008